Rate My Professor Khuloud Al-Jamal

Professor Khuloud T. Al-Jamal is the Chair of Drug Delivery & Nanomedicine and Professor of Drug Delivery & Nanomedicine in the Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine at King's College London. She previously served as Head of Medicines Development. A registered pharmacist with the General Pharmaceutical Council, she completed pre-registration pharmacy training at University College London Hospital. She earned her PhD in Drug Delivery from the School of Pharmacy, University of London in 2005, supported by the Overseas Research Award Scheme Scholarship from 2000 to 2004. Following her doctorate, she held the CW Maplethorpe Research and Teaching Postdoctoral Fellowship from the University of London from 2005 to 2007, investigating cationic dendrimers as anti-angiogenic agents for inhibiting solid and metastatic tumor growth. She commenced her academic career at King's College London as a lecturer in 2011, advancing to her current professorial roles. She also holds a Postgraduate Certificate from King's College London awarded in 2013.

Professor Al-Jamal's research focuses on nanomedicine, encompassing the synthesis and characterization of novel nanomaterials for theranostic applications, pharmacokinetic studies, live small animal imaging using SPECT/CT and MRI, RNAi, gene delivery, magnetic drug targeting, stem cell research, drug delivery across the blood-brain barrier, and multicellular tumor spheroid cultures. She has extensive expertise in designing nanoscale delivery systems such as dendrimers, liposomes, quantum dots, polymers, viral vectors, chemically functionalized carbon nanotubes, and graphene oxide for pre-clinical translation of drugs, proteins, nucleic acids, and radionuclides in therapeutic and diagnostic contexts. Her work has secured funding from organizations including the Royal Society, Worldwide Cancer Research, EPSRC, BBSRC, FP6, FP7, and ITN Marie Curie programs. Notable awards include the BBSRC New Investigator Award in 2012 for carbon nano-needles in blood-brain barrier delivery, the Royal Pharmaceutical Society Science Award in 2012 for achievements in nanomedicine, and three Wellcome Trust Image Awards from 2014 to 2016. Key publications feature 'The interaction of carbon nanotubes with an in vitro blood-brain barrier model' (Biomaterials, 2015), 'Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth' (PNAS, 2010), 'Multiwalled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics' (2008), 'CD47 Knock-Out Using CRISPR-Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo' (Advanced Science, 2025), and 'Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma' (Advanced Drug Delivery Reviews, 2026). Her research has garnered over 11,800 citations, demonstrating substantial influence in pharmaceutical sciences and nanomedicine.